Limits...
Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia.

Miwa K, Nishino Y, Kikuchi M, Masue T, Moriyama Y, Deguchi T - Cent European J Urol (2011)

Bottom Line: Outcomes were evaluated by the International Prostate Symptom Score (IPSS) and quality of life index (QOL), Athens Insomnia Scale (AIS) and nocturia-quality of life index (nocturia-QOL).Among 20 patients, 16 patients were suspected to have sleep disturbances (AIS ≥6).In these patients, additional therapy with tamsulosin and zolpidem significantly reduced nocturia episodes (3.3 ±0.8 to 1.9 ±0.7, p <0.001), AIS (10.6 ±2.9 to 6.8 ±25, p <0.001) and nocturia - QOL (5.6 ±0.5 to 3.6 ±1.1, p <0.001) compared with patients after treatment with tamsulosin only.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Gifu University School of Medicine, Gifu, Japan.

ABSTRACT

Introduction: We examined the efficacy of combination therapy with α1-blocker tamsulosin and hypnotic zolpidem in patients who had suffered from sleep disturbance associated with nocturia.

Material and methods: A total of 35 patients diagnosed with nocturia with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) were studied. After treatment with tamsulosin for 4 weeks, 16 patients dissatisfied with nocturia (nocturiaquality of life index ≥4) and suspected to have sleep disturbance (Athens Insomnia Scale ≥6) received additional treatment with tamsulosin and zolpidem for 2 weeks. Outcomes were evaluated by the International Prostate Symptom Score (IPSS) and quality of life index (QOL), Athens Insomnia Scale (AIS) and nocturia-quality of life index (nocturia-QOL).

Results: After monotherapy with tamsulosin, significant reductions in IPSS (18.9 ±3.8 to 9.9 ±3.0, p <0.001), QOL (4.5 ±0.9 to 3.2 ±0.9, p <0.001) and nocturia episodes (3.4 ±0.7 to 2.6 ±1.0, p <0.001) were observed. However 20 patients were dissatisfied with nocturia (nocturia- QOL ≥4). Among 20 patients, 16 patients were suspected to have sleep disturbances (AIS ≥6). In these patients, additional therapy with tamsulosin and zolpidem significantly reduced nocturia episodes (3.3 ±0.8 to 1.9 ±0.7, p <0.001), AIS (10.6 ±2.9 to 6.8 ±25, p <0.001) and nocturia - QOL (5.6 ±0.5 to 3.6 ±1.1, p <0.001) compared with patients after treatment with tamsulosin only.

Conclusions: Combination therapy with tamsulosin and zolpidem may be useful for patients with BPH dissatisfied with nocturia and suspected to have sleep disturbance.

No MeSH data available.


Related in: MedlinePlus

Enrollment and follow-up of patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3921753&req=5

Figure 0001: Enrollment and follow-up of patients.

Mentions: Enrollment and follow-up of patients in the present study are shown in Figure 1. After assessment at baseline, the 35 patients were administered tamsulosin (0.2 mg/day) for 4 weeks before re-assessment. A nocturia-QOL score of ≤3 was regarded as indicating patient satisfaction with nocturia (defined as Group A), and a nocturia-QOL score of ≥4 was regarded as indicating patient dissatisfaction with nocturia. Patients dissatisfied with nocturia and with sleep disturbances (AIS ≥6) received additional treatment with zolpidem 5-10 mg once per night for 2 weeks (defined as Group B).


Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia.

Miwa K, Nishino Y, Kikuchi M, Masue T, Moriyama Y, Deguchi T - Cent European J Urol (2011)

Enrollment and follow-up of patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3921753&req=5

Figure 0001: Enrollment and follow-up of patients.
Mentions: Enrollment and follow-up of patients in the present study are shown in Figure 1. After assessment at baseline, the 35 patients were administered tamsulosin (0.2 mg/day) for 4 weeks before re-assessment. A nocturia-QOL score of ≤3 was regarded as indicating patient satisfaction with nocturia (defined as Group A), and a nocturia-QOL score of ≥4 was regarded as indicating patient dissatisfaction with nocturia. Patients dissatisfied with nocturia and with sleep disturbances (AIS ≥6) received additional treatment with zolpidem 5-10 mg once per night for 2 weeks (defined as Group B).

Bottom Line: Outcomes were evaluated by the International Prostate Symptom Score (IPSS) and quality of life index (QOL), Athens Insomnia Scale (AIS) and nocturia-quality of life index (nocturia-QOL).Among 20 patients, 16 patients were suspected to have sleep disturbances (AIS ≥6).In these patients, additional therapy with tamsulosin and zolpidem significantly reduced nocturia episodes (3.3 ±0.8 to 1.9 ±0.7, p <0.001), AIS (10.6 ±2.9 to 6.8 ±25, p <0.001) and nocturia - QOL (5.6 ±0.5 to 3.6 ±1.1, p <0.001) compared with patients after treatment with tamsulosin only.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Gifu University School of Medicine, Gifu, Japan.

ABSTRACT

Introduction: We examined the efficacy of combination therapy with α1-blocker tamsulosin and hypnotic zolpidem in patients who had suffered from sleep disturbance associated with nocturia.

Material and methods: A total of 35 patients diagnosed with nocturia with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) were studied. After treatment with tamsulosin for 4 weeks, 16 patients dissatisfied with nocturia (nocturiaquality of life index ≥4) and suspected to have sleep disturbance (Athens Insomnia Scale ≥6) received additional treatment with tamsulosin and zolpidem for 2 weeks. Outcomes were evaluated by the International Prostate Symptom Score (IPSS) and quality of life index (QOL), Athens Insomnia Scale (AIS) and nocturia-quality of life index (nocturia-QOL).

Results: After monotherapy with tamsulosin, significant reductions in IPSS (18.9 ±3.8 to 9.9 ±3.0, p <0.001), QOL (4.5 ±0.9 to 3.2 ±0.9, p <0.001) and nocturia episodes (3.4 ±0.7 to 2.6 ±1.0, p <0.001) were observed. However 20 patients were dissatisfied with nocturia (nocturia- QOL ≥4). Among 20 patients, 16 patients were suspected to have sleep disturbances (AIS ≥6). In these patients, additional therapy with tamsulosin and zolpidem significantly reduced nocturia episodes (3.3 ±0.8 to 1.9 ±0.7, p <0.001), AIS (10.6 ±2.9 to 6.8 ±25, p <0.001) and nocturia - QOL (5.6 ±0.5 to 3.6 ±1.1, p <0.001) compared with patients after treatment with tamsulosin only.

Conclusions: Combination therapy with tamsulosin and zolpidem may be useful for patients with BPH dissatisfied with nocturia and suspected to have sleep disturbance.

No MeSH data available.


Related in: MedlinePlus